NCT05038397 (Therasphere) is a NA clinical trial of Theraspere in Carcinoma, Hepatocellular, sponsored by MedicalExcellence.

Who is sponsoring NCT05038397?

NCT05038397 is sponsored by MedicalExcellence.

What drugs are being tested in NCT05038397?

Interventions in NCT05038397: Theraspere.

What condition does NCT05038397 study?

NCT05038397 studies Carcinoma, Hepatocellular.

Is NCT05038397 still recruiting?

NCT05038397 is currently completed. Last updated 9 September 2021.

Last reviewed 2021-09-09 · How we verify

NCT05038397: Therasphere

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate Efficacy and Safety of TheraSphere and Resection Combination Therapy in Patients With Single Large ((> 5cm, Long Diameter ) Hepatocellular Carcinoma : Exploratory Trial

Completed NA Last updated 9 September 2021

What this trial tests

NA trial testing Theraspere in Carcinoma, Hepatocellular in 30 participants. Completed in 2 June 2021.

Timeline

30 January 2018

Primary endpoint
2 June 2021

2 June 2021

Quick facts

Lead sponsor	MedicalExcellence
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	30 January 2018
Primary completion	2 June 2021
Estimated completion	2 June 2021
Sites	1 location across South Korea

Drugs / interventions tested

Theraspere

Conditions studied

Carcinoma, Hepatocellular — all drugs for Carcinoma, Hepatocellular →

Sponsor

MedicalExcellence

Who can join

19 and older, any sex, with Carcinoma, Hepatocellular. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A study to evaluate efficacy and safety of TheraSphere and resection combination therapy in patients with single large ((\> 5cm, long diameter ) hepatocellular carcinoma :

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Carcinoma, Hepatocellular

Currently open trials in the same condition.

NCT07010497 — A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Be · Phase 2 · recruiting
NCT07227012 — Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatmen · Phase 1, PHASE2 · recruiting
NCT06742892 — A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to · Phase 2 · recruiting
NCT06422403 — A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers · Phase 2 · recruiting
NCT06349980 — A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 with or W · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05038397 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by MedicalExcellence
Last refreshed: 9 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05038397.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing